lystn

Title: Understanding Thyroid Eye Disease and Treatment Options Host: Dawn Berndt, DNP, RN, CRNI® – INS Clinical Education a Publications Manager Guests:  Sara Tullis Wester, MD - Assistant Clinical Professor, University of Miami, Bascom Palmer Eye Institute • Mary Alexander, MA, RN, CRNI®, CAE, FAAN – Infusion Nurses Society Chief Executive Officer Sponsor: Horizon Therapeutics is a bio pharmaceutical company that is driven to deliver breakthrough medicines to patients because Horizon understands the challenges they face.Thyroid Eye Disease and Treatment Options Dr. Sara Wester, MD, Assistant Clinical Professor, University of Miami, Bascom Palmer Eye Institute, shares her expertise in this discussion on thyroid eye disease. She describes the risk factors, incidence, signs and symptoms, as well as treatments for this disease.  Thyroid Eye Disease (TED) is a serious progressive, debilitating autoimmune disease with a limited window, of active disease during which it may respond to pharmacologic intervention. While TED often occurs in people living with hyperthyroidism or Graves’ disease, it is a distinct disease that is caused by autoantibodies activating an IGF-1R-mediated signaling complex on cells within the orbit. This leads to a cascade of negative effects, which cause long-term, irreversible damage. Active TED lasts for up to three years and is characterized by inflammation and tissue expansion behind the eye. As TED progresses, it causes serious damage – including proptosis (eye bulging), strabismus (misalignment of the eyes), and diplopia (double vision) – and in some cases can lead to blindness. People living with TED often experience long-term functional, psychological and economic burdens, including inability to work and perform activities of daily living. (Horizon Therapeutics) INSide INS with Mary Alexander, INS CEO Join Mary Alexander, MA, RN, CRNI®, Chief Executive Officer of the Infusion Nurses Society, as she discusses INS member recognition and scholarship programs, upcoming opportunities for INS membership involvement, and the INS 2020 annual conference in Las Vegas, Nevada.   Dear IVy Answers Your Clinical Questions. This week, Dear IVy tackles this clinical question:  Dear IVy, Why do we have to cleanse the needleless connector between each separate syringe access, when administering medication in a PICC, using the SASH technique? My nurse colleagues and I hold the needleless connector in such a way that it does not touch anything as we pick up each syringe and attach and detach throughout the process. It seems so cumbersome to stop the process, re-cleanse the needleless connector (that we believe has been maintained in aseptic condition), before attaching the next syringe. Are you certain we must continue to cleanse the needleless connector between each access? Signed, Too many “scrub the hubs” for SASH Resources: • Horizon Therapeutics: https://www.horizontherapeutic...  • New infusion therapy approved for thyroid eye disease: https://ir.horizontherapeutics...  • INS Gardner Foundation Scholarship Application: https://images.magnetmail.net/...  • INS Awards and Recognition: https://www.ins1.org/membershi...